-
Primary Research and View of the Future
“View of the Future.” It’s critical to understand the current landscape for each client’s service offerings, but understanding what respondents -
The Disruptor26 Podcast Series with Paul Garofolo
Locus Biosciences is revolutionizing the treatment of bacterial disease using its CRISPR-Cas3 technology to kill targeted bacteria while leaving the -
2020 Q1 BCI – Fundamentals of Running a Biopharmaceutical
The Biopharma CEO Confidence Index is a forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry’s -
Market Opportunity Assessment
Situation: An innovative preclinical CRO with multiple disruptive service offerings retained Kineticos to conduct an evaluation of each of their -
503B Compounding Pharmacy Market Assessment
Situation: A global biopharma company was interested in a comprehensive evaluation of the 503B compounding pharmacy market. The client was -
The Role of Confirmation Bias in Decision Making
Written by Abe Maingi, VP of Precision Medicine, Kineticos Confirmation bias is our tendency to search for and favor all -
Primary Research Study
Kineticos conducted primary research via KOLs and an online survey to give our client qualitative and quantitative data to support -
Are we Manufacturing the right T-Cells And a Look at the Future of Oncology Precision Medicine
The final part of the discussion between Kineticos’ Operating Executive, Steve Buckanavage and Precision Biosciences’ CMO, Christopher Heery M.D., covers -
Is Precision Medicine in Oncology Narrowing Patient Population Too Much?
Kineticos’ Operating Executive Steve Buckanavage, continues his discussion with Christopher Heery, M.D., CMO at Precision Biosciences as they tackle the -
Can We Create Companion Diagnostics In Oncology With What We Know About Biomarkers?
As we continue our discussion between Steve Buckanavage, Kineticos’ Operating Executive and Christopher Heery, M.D., CMO at Precision Biosciences, we
